Ann: Cynata Extends FUJIFILM Licence Option in GvHD, page-219

its not just about screening donors, it’s about cell “senescence”. There is no way around it with bone marrow derived MSCs (well maybe some improvements can be achieved over time) if you want a product that can be produced at an industrial scale. IPSCs, on the other hand, can be virtually infinitely expanded, meaning Cynata can derive all of the cells it will ever need from one uniform donor.

If by ramping you mean simply stating facts, then I agree with you.

Fujifilm will probably exercise their option and perhaps more. It’s splatted all over their presentations earlier this year. Until such time, happy to defend our position to people like you.

In the meantime, enjoy your “additional marketing approval”. It makes me laugh that it’s got you all excited from an investors point of view. It’s exciting that MSBs technology is helping kids with EB, but it will be even more exciting when the treatment can reach the masses and those who cannot afford the enormous price tag of bone marrow derived MSC treatments.